P atients affected by long-lasting and relapsing intestinal inflammation such as ulcerative colitis are at high risk of progressing to colitis-associated cancer (CAC). 1 CAC is a multifactorial disease and involves genetic predisposition, environmental triggers, dysbiosis, as well as an impaired immune system. Chronic inflammation also causes DNA damage and genomic mutations in the epithelium as a result of its requirement to go through numerous regenerative cycles. The sporadic colorectal cancer adenoma-carcinoma sequence involves sequential mutations of key tumor-suppressor genes or oncogenes such as APC, KRAS, and TP53, 2 whereas colitis-associated colorectal cancer instead follows a multistep process called inflammation dysplasia sequence, with TP53 mutations being an early detrimental genetic event. 1 Transforming growth factor b (TGFb) superfamily proteins regulate a variety of cellular functions as well as pathologic processes. TGFb superfamily members include TGFb, activins, and bone morphogenetic proteins (BMPs), among others. TGFb superfamily ligands signal through serine/threonine kinase-receptor subtypes I and II, where the type I receptor is activated upon ligand binding and then associates with the type II receptor. This activated receptor complex leads to the transphosphorylation of the receptorassociated SMAD (R-SMAD) proteins, which include SMAD1, 5, and 8 for the BMPs, and SMAD 2 and 3 for the activins and TGFb. These phosphorylated R-SMADs associate with SMAD4, a shared partner of the TGFb superfamily. This SMAD trimer complex (phosphorylated R-Smads-SMAD4)s then translocates to the nucleus where it activates transcription of specific target genes. Over the years, impairments of the TGFb superfamily signaling pathway in inflammatory bowel disease (IBD) pathogenesis and wound healing process have been studied in experimental models as well as in patients. [3] [4] [5] However, the relationship between CAC and specific elements of the TGFb superfamily signaling, such as the SMADs effectors, has not been studied extensively, with one study investigating the specific role of SMAD7 in lamina propria mononuclear cells as a protective role for CAC in murine models. 6 To date, there has been limited attention directed toward the role played by SMAD effectors within the epithelial compartment in CAC pathogenesis.
In this issue of Cellular and Molecular Gastroenterology and Hepatology, Means et al 7 used a conditional knockout mouse model with an intestinal epithelial deletion of SMAD4 to characterize the homeostatic role of this important TGFb superfamily intracellular effector during experimental colitis. The investigators showed that mice with epithelial deletion of Smad4 presented macroscopic invasive adenocarcinomas of the distal colon and rectum, 3 months after the completion of 3 rounds of treatment with the colonic irritant dextran sulfate sodium. Surprisingly, chronic dextran sulfate sodium treatment alone was sufficient to drive carcinogenesis in mutant mice and the histopathologic analysis of the tumors showed a strong similarity from those derived from human CAC. Lesions found in mice with epithelial deletion of Smad4 followed the inflammation dysplasia sequence 1 because the WNT/b-catenin pathway was not up-regulated and tumors appeared flat or slightly elevated at the mucosal surface with extensive invasion of glands into the submucosa and muscularis mucosa. The development of CAC in these mutant mice was shown to be an early event because colonic carcinomas invading the submucosa already were observed after 2 months in some mice. By using RNA sequencing analysis, Means et al 7 showed a strong inflammatory signature after loss of epithelial Smad4, with deregulated expression of numerous chemokines and cytokines as well as their receptors. From the group of deregulated molecules, C-C motif chemokine 20 (CCL20) was of particular interest because it is known to play a role in IBD as well as in colon cancer. Means et al 7 then used elegant in vitro studies involving conditionally immortalized Smad4 fl/fl cell lines as well as rectal cancer-derived human tumoroids to confirm the central role played by SMAD4 in repression of CCL20 gene expression in colonic epithelial cells. In addition, they explored mechanisms by which epithelial colonic TGFb/BMP signaling, through the SMAD4 intracellular effector, interacts with cytokine and chemokine expression. Again using in vitro models, Means et al 7 showed that TGFb signaling, as well as BMP signaling, could block the induction of CCL20 in a cell-autonomous manner when used as a prophylactic treatment or after an inflammatory trigger such as tumor necrosis factor, interleukin 1b, or lipopolysaccharides.
This study by Means et al 7 provides new insight into the importance of the TGFb/BMP signaling pathways within the colonic epithelium and its relevance regarding gastrointestinal pathologies such as IBD and CAC. As Means et al 7 showed, loss of Smad4 in the colonic epithelium implicates an important deregulation of cytokine and chemokine expression, thus leading to an increase of professional immune cell infiltration in the colonic submucosa, inevitably modifying the subepithelial microenvironment. How this dysfunctional microenvironment impacts the development of CAC in the long run will need to be investigated in future studies and could lead to translational insight involving regulation of these morphogenetic pathways for the treatment of the disease. 
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